XB
XBiotech Inc.
XBIT · NASDAQ
$2.15 -1.83% (-$0.04)
1M -3.52%
Market Cap $65.5M
P/E Ratio -
Div. Yield -
ROE 31.62%
Bulios Fair Price
$1.08
49.8% downside
Current Price
$2.15
Undervalued Fair Value Overvalued
According to Bulios Fair Price, XBIT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.51x
EV/FFO N/A
P/E N/A
Growth
0 /100
Declining Book val. growth 16.42%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 33.77%
ROIC 37.23%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 33.15x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
58 /100
Moderate Profitable years 0
Beta 0.85x
EPS volatility 40.31%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about XBIT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sushma Shivaswamy
Employees
87
Headquarters
Austin